Poster presentation describes Phase 2 study assessing safety and efficacy of topical pravibismane in subjects suffering from moderate infections associated with chronic diabetic foot ulcers Phase 2 study is funded,… Read More
Kenneth P. Judge Brings Strong Strategic Commercial Development and Global M&A Experience to Renaissance VANCOUVER, BC — Renaissance BioScience Corp., a leader in bioengineering for the global agriculture and food… Read More
VICTORIA, BC — /CNW/ — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its… Read More
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A receptor antagonist,… Read More
Net loss for the first six months of 2023 decreased by 45% as compared to the same period in 2022 Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at… Read More
